CLINDAMYCIN-M is a medicine from the group of antibiotics-lincosamides, has a wide spectrum of action, bacteriostatic. Active against many pathogens of infectious diseases, including Streptococcus pneumoniae – the causative agent of premonia.

Due to its high activity, CLINDAMYCIN can be used to treatment of many infectious and inflammatory diseases caused by microorganisms sensitive to CLINDAMYCIN.

When taken orally, clindamycin hydrochloride is rapidly and well absorbed from the gastrointestinal tract (better than lincomycin), bioavailability is 90%, simultaneous food intake slows down absorption without changing the degree of absorption.

Protein binding – 92–94%.

CLINDAMYCIN easily penetrates into biological fluids and organs of the body, incl. tonsils (approximately 40% of the concentration in the blood), bronchi, lungs, pleura, pleural fluid (50–90%), saliva, sputum (30–75%).


1 capsule contains clindamycin hydrochloride in terms of clindamycin 0.15 g (150 mg)

Excipients: calcium stearate, lactose, colloidal silicon dioxide, sodium methylparaben, sodium propylparaben, gelatin, titanium dioxide, tartrazine, erythrosine, brilliant blue, amaranth.


acute and chronic infections of the female reproductive system

infections of the lower respiratory tract (pneumonia, including aspiration, bronchitis, lung abscess, pleural empyema)

infections of the upper respiratory tract and infections of the ENT organs (tonsillitis, pharyngitis, sinusitis, otitis media)


CLINDAMYCIN-M should be taken with a sufficient amount of liquid (at least 1 large glass of water) to avoid possible irritation of the esophagus.

In case of suspicion of infection caused by β-hemolytic streptococcus, or in the case of signs of β-hemolytic streptococcus, treatment should be for at least 10 days.


Depending on the location and severity of the infection, adults and children over 14 years old should use 4-12 capsules per day (equivalent to 0.6-1.8 g of clindamycin).

The daily dose is divided into 4 doses.